Abstract:Purpose/Objective(s) Clinically relevant biomarkers for anti-programmed death (PD)-1 therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) are limited to PD ligand-1 combined proportion score (PD-L1 CPS) on tumor biopsies. Cytokines are soluble proteins that act as a bridge between innate immunity, inflammation, and cancer. Given the interest in circulating biomarkers, this study sought to evaluate pre- and post-treatment serum cytokine expression signatures in R/M HNSCC treated with anti-PD-1 therapy. Materials/Methods In this ongoing, prospective multi-center study, 33 paired pre- and post-treatment (cycle 2 day 1) blood samples were analyzed for 92 cytokine biomarkers (Olink Target 96 Immuno-Oncology) in patients with R/M HNSCC on anti-PD-1-based therapy. Associations between pre-treatment, post-treatment, and change of pre- to post-treatment cytokine levels, overall survival (OS), and progression-free survival (PFS) were assessed using Kaplan-Meier curves, multivariable Cox proportional hazards (adjusted for age, sex, smoking, PD-L1 CPS, ECOG performance status, and platelet count), and unsupervised clustering analyses. Results There was a statistically significant association between pre-treatment cytokine expression signature, and both immune composition (e.g., relative fractions of circulating immune cell subtypes) and platelet count. Comparing pre- and post-treatment samples, expression levels of most cytokines exhibited a statistically significant increase (p <0.05). In pre-treatment samples, several cytokines exhibited nominally statistically significant associations (p < 0.05) with both OS and PFS in multivariable model. Similar results were seen in analyses of serum cytokines with PFS in post-treatment samples. Machine learning analysis using Elastic Net models identified a panel of cytokines (CD40.L, EGF, ANGPT1, MCP.4, CXCL1, IL10) that predicted survival with high prognostic performance (Cross Validated C-index of 0.75) in pre-treatment samples. Notably, a different panel of cytokines (ANGPT1, IL10, FGF2, TNFSF14, Gal.1, HGF, PTN, VEGFA, CCL20) predicted survival with even higher prognostic performance (Cross Validated C-index of 0.90) in post-treatment samples. Unsupervised clustering analysis based on the change in pre- versus post-treatment cytokine expression identified two subgroups which differed in their survival trajectories (log-rank p =0.09 and 0.01 for OS and PFS, respectively), where the subgroup with smaller changes in serum cytokine levels was associated with higher survival. Conclusion Our results highlight the potential prognostic and predictive value of serum cytokine expression signatures in R/M HNSCC treated with anti-PD-1 therapy and underscore the importance of longitudinal on-treatment assessments in peripheral blood.

Ultra‐high combined positive score and high serum albumin are favorable prognostic biomarkers for immune checkpoint inhibitors in head and neck squamous cell carcinoma

Abstract 3852: Comprehensive genomic profiling of recurrent or metastatic head and neck cancer presenting with combined positive score 90 or more

Combined Positive Score and Cisplatin Sensitivity Are Prognostic Factors for Response to Nivolumab Therapy for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck

Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma

Serum albumin and derived neutrophil-to-lymphocyte ratio are potential predictive biomarkers for immune checkpoint inhibitors in small cell lung cancer

Predictive Effects of a Combined Indicator in Patients with Hepatocellular Carcinoma after Thermal Ablation.

Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2

Serum Albumin as an Independent Predictor of Long-Term Survival in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab

Abstract 7621: Serum albumin and derived neutrophil-to-lymphocyte ratio are potential predictive biomarkers for immune checkpoint inhibitors in small cell lung cancer

C-reactive protein/albumin ratio as prognostic score in oral squamous cell carcinoma

Cholesterol and C-reactive Protein Prognostic Score Predicted Prognosis of Immune Checkpoint Inhibitors Based Interventional Therapies for Intermediate-to-advanced Hepatocellular Carcinoma Patients.

On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy

Comprehensive Genomic Profiling Reveals Clinical Associations in Response to Immune Therapy in Head and Neck Cancer

Prognostic significance of albumin-bilirubin score in patients with unresectable hepatocellular carcinoma undergoing combined immunotherapy and radiotherapy

Chemotherapy combined with immune checkpoint inhibitors may overcome the detrimental effect of high neutrophil-to-lymphocyte ratio prior to treatment in esophageal cancer patients

Correlation between the Immune Checkpoint Inhibitors Prognostic Index and Outcomes in Nonsmall Cell Lung Cancer: A Multicentre Analysis

Pre- and Post-treatment Serum Cytokine Expression Signatures and Survival Outcomes in Patients with Head and Neck Squamous Cell Cancer on Anti-PD-1 Therapy

Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma

Positron Emission Tomography-Computed Tomography Parameters Predict Efficacy of Immunotherapy in Head and Neck Squamous Cell Carcinomas.

Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment

Potential of Nutritional Markers as Predictors After Immunotherapy in Advanced Head and Neck Squamous Cell Carcinoma